Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.
Stocks · News reference
Reported Earlier, Enliven To Present New ELVN-001 Blood Cancer Trial Data At September Medical Meeting
Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating
William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating.
Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78
Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $78.